MetaVia Inc. Files 8-K for Regulation FD and Financials
Ticker: MTVA · Form: 8-K · Filed: Aug 4, 2025 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Metavia INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Aug 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, financial-statements, corporate-history
Related Tickers: MTVA
TL;DR
MetaVia Inc. (MTVA) filed an 8-K on Aug 4, 2025, for Reg FD and financials. Formerly NeuroBo/Gemphire.
AI Summary
MetaVia Inc. filed an 8-K on August 4, 2025, to report information under Regulation FD and to file financial statements and exhibits. The company, formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc., is incorporated in Delaware and headquartered in Cambridge, MA.
Why It Matters
This filing provides an official update on MetaVia Inc.'s regulatory disclosures and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing for financial statements and regulatory disclosures, not indicating any specific adverse events.
Key Players & Entities
- MetaVia Inc. (company) — Registrant
- August 4, 2025 (date) — Date of Report
- NeuroBo Pharmaceuticals, Inc. (company) — Former Company Name
- Gemphire Therapeutics Inc. (company) — Former Company Name
- Cambridge, Massachusetts (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by MetaVia Inc.?
The primary purpose of this 8-K filing is to report information under Regulation FD Disclosure and to file Financial Statements and Exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on August 4, 2025.
What were MetaVia Inc.'s previous names?
MetaVia Inc. was formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc.
Where are MetaVia Inc.'s principal executive offices located?
MetaVia Inc.'s principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 4, 2025 regarding MetaVia Inc. (MTVA).